BiotechTube

Placebo + AZD3480 + AZD3480

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

May 1, 2008 → Jul 1, 2009

NCT ID
NCT00683462

About Placebo + AZD3480 + AZD3480

Placebo + AZD3480 + AZD3480 is a phase 2 stage product being developed by AstraZeneca for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00683462. Target conditions include ADHD.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00683462Phase 2Completed

Competing Products

20 competing products in ADHD

See all competitors
ProductCompanyStageHype Score
atomoxetineEli LillyApproved
85
Strattera (atomoxetine)Eli LillyApproved
85
Atomoxetine + placeboEli LillyApproved
85
Atomoxetine Hydrochloride + placeboEli LillyApproved
85
atomoxetine (Strattera)Eli LillyApproved
85
Atomoxetine + stimulants (any approved ADHD medication)Eli LillyPre-clinical
23
dasotraline + PlaceboSumitomo PharmaPhase 3
77
dasotralineSumitomo PharmaPhase 1
33
dasotraline 4mgSumitomo PharmaPhase 3
77
AZD1446 + AZD1446 + AZD1446 + PlaceboAstraZenecaPhase 2
52
MK0249 + Concerta (methylphenidate) + PlaceboMerckPhase 2
52
Focalin XRNovartisPhase 3
77
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + PlaceboNovartisApproved
85
Dexmethylphenidate HCl extended-release capsulesNovartisPhase 3
77
Methylphenidate hydrochlorideNovartisPhase 3
77
Focalin XRNovartisPhase 3
77
methylphenidate HCl ERCT + PlaceboPfizerApproved
84
methylphenidate HCl ERCTPfizerApproved
84
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XRPfizerApproved
84
BrexpiprazoleLundbeckPhase 1
30

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85